Arvinas (ARVN) Revenue & Revenue Breakdown
Arvinas Revenue Highlights
Latest Revenue (Y)
$78.50M
Latest Revenue (Q)
$76.50M
Arvinas Revenue by Period
Arvinas Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $78.50M | -40.26% |
| 2022-12-31 | $131.40M | 181.37% |
| 2021-12-31 | $46.70M | 114.20% |
| 2020-12-31 | $21.80M | -49.27% |
| 2019-12-31 | $42.98M | 200.03% |
| 2018-12-31 | $14.32M | 89.00% |
| 2017-12-31 | $7.58M | 13.64% |
| 2016-12-31 | $6.67M | - |
Arvinas generated $78.50M in revenue during NA 2023, up -40.26% compared to the previous quarter, and up 548.03% compared to the same period a year ago.
Arvinas Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $76.50M | 202.37% |
| 2024-03-31 | $25.30M | -158.70% |
| 2023-12-31 | $-43.10M | -224.57% |
| 2023-09-30 | $34.60M | -36.51% |
| 2023-06-30 | $54.50M | 67.69% |
| 2023-03-31 | $32.50M | -14.47% |
| 2022-12-31 | $38.00M | 25.41% |
| 2022-09-30 | $30.30M | -3.19% |
| 2022-06-30 | $31.30M | 29.34% |
| 2022-03-31 | $24.20M | -7.98% |
| 2021-12-31 | $26.30M | 183.26% |
| 2021-09-30 | $9.28M | 67.46% |
| 2021-06-30 | $5.54M | 0.09% |
| 2021-03-31 | $5.54M | 149.78% |
| 2020-12-31 | $2.22M | -70.81% |
| 2020-09-30 | $7.60M | 32.17% |
| 2020-06-30 | $5.75M | -7.88% |
| 2020-03-31 | $6.24M | 27.51% |
| 2019-12-31 | $4.89M | -83.72% |
| 2019-09-30 | $30.05M | 648.17% |
| 2019-06-30 | $4.02M | - |
| 2019-03-31 | $4.02M | 16.75% |
| 2018-12-31 | $3.44M | 1.92% |
| 2018-09-30 | $3.38M | -0.72% |
| 2018-06-30 | $3.40M | -17.25% |
| 2018-03-31 | $4.11M | 59.73% |
| 2017-12-31 | $2.57M | 54.13% |
| 2017-09-30 | $1.67M | - |
| 2017-06-30 | $1.67M | - |
| 2017-03-31 | $1.67M | - |
Arvinas generated $76.50M in revenue during Q2 2024, up 202.37% compared to the previous quarter, and up 235.38% compared to the same period a year ago.
Arvinas Revenue Breakdown
Arvinas Revenue Breakdown by Product
Quarterly Revenue by Product
| Product/Service | Jun 24 |
|---|---|
| License | $130.00M |
Arvinas's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: License (100.00%).
Arvinas Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RARE | Ultragenyx Pharmaceutical | $434.25M | $147.03M |
| KYMR | Kymera Therapeutics | $78.59M | $10.29M |
| ARVN | Arvinas | $78.50M | $76.50M |
| NRIX | Nurix Therapeutics | $76.99M | $12.09M |
| FHTX | Foghorn Therapeutics | $34.16M | $6.89M |
| RLAY | Relay Therapeutics | $25.55M | - |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| CRNX | Crinetics Pharmaceuticals | $4.01M | $640.00K |
| IPSC | Century Therapeutics | $2.23M | $771.00K |
| STTK | Shattuck Labs | $1.66M | $1.61M |
| PLRX | Pliant Therapeutics | $1.58M | - |
| BDTX | Black Diamond Therapeutics | - | - |
| CCCC | C4 Therapeutics | - | - |
| KURA | Kura Oncology | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
ARVN Revenue FAQ
What is Arvinas’s yearly revenue?
Arvinas's yearly revenue for 2023 was $78.5M, representing a decrease of -40.26% compared to 2022. The company's yearly revenue for 2022 was $131.4M, representing an increase of 181.37% compared to 2021. ARVN's yearly revenue for 2021 was $46.7M, representing an increase of 114.20% compared to 2020.
What is Arvinas’s quarterly revenue?
Arvinas's quarterly revenue for Q2 2024 was $76.5M, a 202.37% increase from the previous quarter (Q1 2024), and a 40.37% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $25.3M, a -158.70% decrease from the previous quarter (Q4 2023), and a -22.15% decrease year-over-year (Q1 2023). ARVN's quarterly revenue for Q4 2023 was $-43.1M, a -224.57% decrease from the previous quarter (Q3 2023), and a -213.42% decrease year-over-year (Q4 2022).
What is Arvinas’s revenue growth rate?
Arvinas's revenue growth rate for the last 3 years (2021-2023) was 68.09%, and for the last 5 years (2019-2023) was 82.66%.